## ROL: Rollins, Inc. - XLY: Consumer Cyclical

### Executive Summary

No thesis match: MRS_20 0.5% below STRENGTH zone (4.0-10.0%); PEG 3.96 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-1.5% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($59.34)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 6, Bearish: 0)

**1. Barclays upgrades Rollins stock to Overweight on growth potential**
- Source: Investing.com | 20251205T070554 | Bullish | Relevance: 100%
- Barclays has upgraded Rollins (NYSE:ROL) stock from Equalweight to Overweight and increased its price target to $72.00 from $60.00, citing incremental opportunities for growth and the company's strong year-to-date performance. The pest control company has seen significant revenue growth and is undergoing a transformation under new leadership, contributing to investor confidence. Bernstein also reiterated an Outperform rating with a $70.00 price target, highlighting the potential for cost-cutting initiatives.

**2. Barclays upgrades Rollins stock to Overweight on growth potential**
- Source: Investing.com | 20251205T015000 | Bullish | Relevance: 100%
- Barclays has upgraded Rollins (NYSE:ROL) from Equalweight to Overweight, raising its price target to $72.00 from $60.00, citing "incremental opportunities for enhancing/providing upside to the existing growth framework." This upgrade comes as Rollins' stock has significantly outperformed the broader market, with 11.17% revenue growth over the last twelve months. The new price target reflects increased confidence in the company's outlook following meetings with management.

**3. ROL SEC Filings - Rollins 10-K, 10-Q, 8-K Forms**
- Source: Stock Titan | 20251204T140923 | Neutral | Relevance: 100%
- This page on Stock Titan provides comprehensive access to Rollins Inc. (ROL) SEC filings, including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms. It features AI-powered summaries of these documents, real-time EDGAR updates, and contextual analytics to help investors understand the company's financial performance and insider activity. The page highlights several recent filings, including secondary offerings, Q3 revenue growth, and insider transactions.

**4. Barclays upgrades Rollins stock to Overweight on growth potential By Investing.com**
- Source: Investing.com Nigeria | 20251205T090905 | Bullish | Relevance: 100%
- Barclays has upgraded Rollins (NYSE:ROL) from Equalweight to Overweight and increased its price target to $72.00 from $60.00, citing "incremental opportunities for enhancing/providing upside to the existing growth framework." The pest control company's stock has outperformed the broader market, gaining 31% year-to-date through December 3, 2025, compared to the S&P 500's 16% rise. This upgrade reflects confidence in Rollins' growth outlook, revenue growth of 11.17% over the last twelve months, and its ongoing modernization efforts under new leadership.

**5. Rollins Stock Attracts Major Institutional Interest and Bullish Price Target**
- Source: Primary Ignition | 20251204T111143 | Bullish | Relevance: 100%
- Rollins Inc. is gaining significant attention from Wall Street due to substantial buying activity from institutional investors, including Norges Bank, and a bullish "Outperform" rating with a $70 price target from Bernstein. Despite a premium valuation, the pest control giant demonstrated strong financial performance with 12% revenue growth and increased net income in its latest quarter. All eyes are on the upcoming December 9th analyst day, where management is expected to detail the strategic roadmap and updates on the critical "BOSS" system, which could drive the stock toward its new target.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-05 | Barclays | $72 | $60 | +20% |
| 2025-11-12 | Bernstein | $70 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-05 | Barclays | up | Overweight |
| 2025-11-12 | Bernstein | init | Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 7 ($3296.08M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 24.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 4 |

**Top Holders:**
- Vanguard Group Inc: 7.6% (+4.2%)
- Blackrock Inc.: 6.0% (+1.2%)
- State Street Corpora: 2.5% (+1.4%)
- Kayne Anderson Rudni: 2.0% (-2.8%)
- Geode Capital Manage: 2.0% (+1.7%)

### Key Risks

1. Heavy insider selling: $3296M sold (7 transactions in 90 days).
2. Valuation stretched: PEG 4.0x requires aggressive growth execution.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 3.96 signals overvaluation risk, limited margin of safety. Forward P/E 48.0x stretched relative to 12% growth. Quality metrics strong (ROE 36%, ROA 15%). Analyst sentiment positive (1 raises, avg +20%). Insider selling cluster ($3296.1M in 90 days), potential headwind. Institutional flow bullish (5 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $29.2B |
| Beta | 0.79 |
| 52W Range | $45.34 - $61.84 |
| Short Interest | 3.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 3.96 |
| Forward P/E | 48.0 |
| Current P/E | 53.8 |
| YoY Growth | 12.1% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 2.0% to 0.5% (-1.5% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 3.5pp (needs >4.0% for momentum thesis). MRS_5 at 0.3% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). OFD pattern: +MTL (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 0.47% (CS: 58) | Neutral |
| RSI_14 | 64.1 | Neutral |
| MACD Histogram | 0.04 | Bullish |
| vs SMA20 | 1.028x | Above |
| vs SMA50 | 1.054x | Above |
| vs SMA200 | 1.091x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $61.40
- **Stop Loss:** $59.34 (3.4% risk)
- **Target:** $63.46 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 485
- **Position Value:** $29,779.00
- **Portfolio %:** 29.78%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with balanced risk appetite. VIX near 15th percentile of 52-week range signals calm conditions, while modest yield curve steepening (54bps 10Y-3M) suggests healthy growth expectations. Breadth at 52% indicates selective participation rather than broad-based momentum.*

### Earnings

**Next:** 2026-02-18 (Est: $0.27)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.33 | $0.35 | +6.3% |
| 2025Q2 | $0.30 | $0.30 | -0.7% |
| 2025Q1 | $0.22 | $0.22 | +1.3% |
| 2024Q4 | $0.23 | $0.23 | -0.8% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*